Osteopontin promotes the invasive growth of melanoma cells by activating integrin αvβ3 and down-regulating tetraspanin CD9

American Journal of Pathology

Volumn 184, Issue 3, 2014, Pages 842-858

  Yin, Miao ^a   Soikkeli, Johanna ^a   Jahkola, Tiina ^b   Virolainen, Susanna ^a   Saksela, Olli ^b   Hölttä, Erkki ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; CD9 ANTIGEN; OSTEOPONTIN; VITRONECTIN RECEPTOR;

CELL MOTION; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MELANOMA; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION; UPREGULATION;

ANTIGENS, CD9; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHAVBETA3; MELANOMA; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPONTIN; RECEPTORS, VITRONECTIN; UP-REGULATION;

EID: 84894144242     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.11.020     Document Type: Article

References (101)

1. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, and S. Clegg et al. Mutations of the BRAF gene in human cancer Nature 417 2002 949 954 (Pubitemid 34716871)
2. M.F. Berger, E. Hodis, T.P. Heffernan, Y.L. Deribe, M.S. Lawrence, and A. Protopopov et al. Melanoma genome sequencing reveals frequent PREX2 mutations Nature 485 2012 502 506
3. M. Krauthammer, Y. Kong, B.H. Ha, P. Evans, A. Bacchiocchi, J.P. McCusker, E. Cheng, M.J. Davis, G. Goh, M. Choi, S. Ariyan, D. Narayan, K. Dutton-Regester, A. Capatana, E.C. Holman, M. Bosenberg, M. Sznol, H.M. Kluger, D.E. Brash, D.F. Stern, M.A. Materin, R.S. Lo, S. Mane, S. Ma, K.K. Kidd, N.K. Hayward, R.P. Lifton, J. Schlessinger, T.J. Boggon, and R. Halaban Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma Nat Genet 44 2012 1006 1014
4. F.W. Huang, E. Hodis, M.J. Xu, G.V. Kryukov, L. Chin, and L.A. Garraway Highly recurrent TERT promoter mutations in human melanoma Science 339 2013 957 959
5. S. Horn, A. Figl, P.S. Rachakonda, C. Fischer, A. Sucker, A. Gast, S. Kadel, I. Moll, E. Nagore, K. Hemminki, D. Schadendorf, and R. Kumar TERT promoter mutations in familial and sporadic melanoma Science 339 2013 959 961
6. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
7. A.M. Montgomery, R.A. Reisfeld, and D.A. Cheresh Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen Proc Natl Acad Sci U S A 91 1994 8856 8860 (Pubitemid 2148815)
8. P. Henriet, Z.D. Zhong, P.C. Brooks, K.I. Weinberg, and Y.A. DeClerck Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1 Proc Natl Acad Sci U S A 97 2000 10026 10031
9. E. Kaariainen, P. Nummela, J. Soikkeli, M. Yin, M. Lukk, T. Jahkola, S. Virolainen, A. Ora, E. Ukkonen, O. Saksela, and E. Holtta Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion J Pathol 210 2006 181 191 (Pubitemid 44463933)
10. J. Soikkeli, M. Lukk, P. Nummela, S. Virolainen, T. Jahkola, R. Katainen, L. Harju, E. Ukkonen, O. Saksela, and E. Holtta Systematic search for the best gene expression markers for melanoma micrometastasis detection J Pathol 213 2007 180 189 (Pubitemid 47612240)
11. M. Yin, J. Soikkeli, T. Jahkola, S. Virolainen, O. Saksela, and E. Holtta TGF-beta signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells Am J Pathol 181 2012 2202 2216
12. Y. Zhou, D.L. Dai, M. Martinka, M. Su, Y. Zhang, E.I. Campos, I. Dorocicz, L. Tang, D. Huntsman, C. Nelson, V. Ho, and G. Li Osteopontin expression correlates with melanoma invasion J Invest Dermatol 124 2005 1044 1052 (Pubitemid 40629107)
13. J. Rangel, M. Nosrati, S. Torabian, L. Shaikh, S.P. Leong, C. Haqq, J.R. Miller 3rd, R.W. Sagebiel, and M. Kashani-Sabet Osteopontin as a molecular prognostic marker for melanoma Cancer 112 2008 144 150
14. C. Conway, A. Mitra, R. Jewell, J. Randerson-Moor, S. Lobo, J. Nsengimana, S. Edward, D.S. Sanders, M. Cook, B. Powell, A. Boon, F. Elliott, F. de Kort, M.A. Knowles, D.T. Bishop, and J. Newton-Bishop Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival Clin Cancer Res 15 2009 6939 6946
15. A. Bellahcene, and V. Castronovo Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer Am J Pathol 146 1995 95 100
16. H. Singhal, D.S. Bautista, K.S. Tonkin, F.P. O'Malley, A.B. Tuck, A.F. Chambers, and J.F. Harris Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival Clin Cancer Res 3 1997 605 611 (Pubitemid 27211840)
17. A.F. Chambers, S.M. Wilson, N. Kerkvliet, F.P. O'Malley, J.F. Harris, and A.G. Casson Osteopontin expression in lung cancer Lung Cancer 15 1996 311 323 (Pubitemid 26399511)
18. V. Donati, L. Boldrini, M. Dell'Omodarme, M.C. Prati, P. Faviana, T. Camacci, M. Lucchi, A. Mussi, M. Santoro, F. Basolo, and G. Fontanini Osteopontin expression and prognostic significance in non-small cell lung cancer Clin Cancer Res 11 2005 6459 6465 (Pubitemid 41338982)
19. J.H. Kim, S.J. Skates, T. Uede, K.K. Wong, J.O. Schorge, C.M. Feltmate, R.S. Berkowitz, D.W. Cramer, and S.C. Mok Osteopontin as a potential diagnostic biomarker for ovarian cancer JAMA 287 2002 1671 1679 (Pubitemid 34289219)
20. L.H. Bao, H. Sakaguchi, J. Fujimoto, and T. Tamaya Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers J Biomed Sci 14 2007 373 381 (Pubitemid 46855418)
21. Q.H. Ye, L.X. Qin, M. Forgues, P. He, J.W. Kim, A.C. Peng, R. Simon, Y. Li, A.I. Robles, Y. Chen, Z.C. Ma, Z.Q. Wu, S.L. Ye, Y.K. Liu, Z.Y. Tang, and X.W. Wang Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning Nat Med 9 2003 416 423 (Pubitemid 36460075)
22. D. Agrawal, T. Chen, R. Irby, J. Quackenbush, A.F. Chambers, M. Szabo, A. Cantor, D. Coppola, and T.J. Yeatman Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling J Natl Cancer Inst 94 2002 513 521 (Pubitemid 34411290)
23. G.F. Weber, G.S. Lett, and N.C. Haubein Osteopontin is a marker for cancer aggressiveness and patient survival Br J Cancer 103 2010 861 869
24. L.F. Brown, A. Papadopoulos-Sergiou, B. Berse, E.J. Manseau, K. Tognazzi, C.A. Perruzzi, H.F. Dvorak, and D.R. Senger Osteopontin expression and distribution in human carcinomas Am J Pathol 145 1994 610 623 (Pubitemid 24285968)
25. P.H. Anborgh, J.C. Mutrie, A.B. Tuck, and A.F. Chambers Role of the metastasis-promoting protein osteopontin in the tumour microenvironment J Cell Mol Med 14 2010 2037 2044
26. D.T. Denhardt, C.M. Giachelli, and S.R. Rittling Role of osteopontin in cellular signaling and toxicant injury Annu Rev Pharmacol Toxicol 41 2001 723 749 (Pubitemid 32385904)
27. G.F. Weber The metastasis gene osteopontin: a candidate target for cancer therapy Biochim Biophys Acta 1552 2001 61 85 (Pubitemid 34124131)
28. S.R. Rittling, and A.F. Chambers Role of osteopontin in tumour progression Br J Cancer 90 2004 1877 1881 (Pubitemid 38746324)
29. R.B. Irby, S.M. McCarthy, and T.J. Yeatman Osteopontin regulates multiple functions contributing to human colon cancer development and progression Clin Exp Metastasis 21 2004 515 523
30. M.D. Castellone, A. Celetti, V. Guarino, A.M. Cirafici, F. Basolo, R. Giannini, E. Medico, M. Kruhoffer, T.F. Orntoft, F. Curcio, A. Fusco, R.M. Melillo, and M. Santoro Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells Oncogene 23 2004 2188 2196 (Pubitemid 38482533)
31. J. Zhao, L. Dong, B. Lu, G. Wu, D. Xu, J. Chen, K. Li, X. Tong, J. Dai, S. Yao, M. Wu, and Y. Guo Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis Gastroenterology 135 2008 956 968
32. G. Chakraborty, S. Jain, and G.C. Kundu Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms Cancer Res 68 2008 152 161 (Pubitemid 351380116)
33. P.Y. Wai, and P.C. Kuo Osteopontin: regulation in tumor metastasis Cancer Metastasis Rev 27 2008 103 118
34. P.H. Anborgh, J.C. Mutrie, A.B. Tuck, and A.F. Chambers Pre- and post-translational regulation of osteopontin in cancer J Cell Commun Signal 5 2011 111 122
35. Y. Yokosaki, N. Matsuura, T. Sasaki, I. Murakami, H. Schneider, S. Higashiyama, Y. Saitoh, M. Yamakido, Y. Taooka, and D. Sheppard The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin J Biol Chem 274 1999 36328 36334
36. G.F. Weber, S. Ashkar, M.J. Glimcher, and H. Cantor Receptor-ligand interaction between CD44 and osteopontin (Eta-1) Science 271 1996 509 512 (Pubitemid 26044470)
37. H. Rangaswami, A. Bulbule, and G.C. Kundu Osteopontin: role in cell signaling and cancer progression Trends Cell Biol 16 2006 79 87 (Pubitemid 43247403)
38. L.A. Shevde, S. Das, D.W. Clark, and R.S. Samant Osteopontin: an effector and an effect of tumor metastasis Curr Mol Med 10 2010 71 81
39. M. Hsu, D.E. Elder, and M. Herlyn The Wistar (WM) Melanoma Cell Lines J.R.W. Masters, B. Palsson, Human Cell Culture 1999 Kluwer Acad London 259 274
40. M.F. Young, J.M. Kerr, J.D. Termine, U.M. Wewer, M.G. Wang, O.W. McBride, and L.W. Fisher cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN) Genomics 7 1990 491 502 (Pubitemid 20244451)
41. A.B. Tuck, D.M. Arsenault, F.P. O'Malley, C. Hota, M.C. Ling, S.M. Wilson, and A.F. Chambers Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells Oncogene 18 1999 4237 4246 (Pubitemid 29377854)
42. T. Funakoshi, I. Tachibana, Y. Hoshida, H. Kimura, Y. Takeda, T. Kijima, K. Nishino, H. Goto, T. Yoneda, T. Kumagai, T. Osaki, S. Hayashi, K. Aozasa, and I. Kawase Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer Oncogene 22 2003 674 687 (Pubitemid 36269281)
43. T. Watsuji, Y. Okamoto, N. Emi, Y. Katsuoka, and M. Hagiwara Controlled gene expression with a reverse tetracycline-regulated retroviral vector (RTRV) system Biochem Biophys Res Commun 234 1997 769 773 (Pubitemid 27281195)
44. P. Nummela, M. Yin, M. Kielosto, V. Leaner, M.J. Birrer, and E. Holtta Thymosin beta4 is a determinant of the transformed phenotype and invasiveness of S-adenosylmethionine decarboxylase-transfected fibroblasts Cancer Res 66 2006 701 712 (Pubitemid 43165932)
45. P. Nummela, J. Lammi, J. Soikkeli, O. Saksela, P. Laakkonen, and E. Holtta Transforming growth factor beta-induced (TGFBI) is an anti-adhesive protein regulating the invasive growth of melanoma cells Am J Pathol 180 2012 1663 1674
46. K. Ravanko, K. Jarvinen, J. Helin, N. Kalkkinen, and E. Holtta Cysteine cathepsins are central contributors of invasion by cultured adenosylmethionine decarboxylase-transformed rodent fibroblasts Cancer Res 64 2004 8831 8838 (Pubitemid 39665486)
47. M. Kielosto, P. Nummela, R. Katainen, V. Leaner, M.J. Birrer, and E. Holtta Reversible regulation of the transformed phenotype of ornithine decarboxylase- and ras-overexpressing cells by dominant-negative mutants of c-Jun Cancer Res 64 2004 3772 3779 (Pubitemid 38697286)
48. J. Soikkeli, P. Podlasz, M. Yin, P. Nummela, T. Jahkola, S. Virolainen, L. Krogerus, P. Heikkila, K. von Smitten, O. Saksela, and E. Holtta Metastatic outgrowth encompasses COL-I, FN1, and POSTN up-regulation and assembly to fibrillar networks regulating cell adhesion, migration, and growth Am J Pathol 177 2010 387 403
49. A. Paasinen-Sohns, E. Kaariainen, M. Yin, K. Jarvinen, P. Nummela, and E. Holtta Chaotic neovascularization induced by aggressive fibrosarcoma cells overexpressing S-adenosylmethionine decarboxylase Int J Biochem Cell Biol 43 2011 441 454
50. N. Pampori, T. Hato, D.G. Stupack, S. Aidoudi, D.A. Cheresh, G.R. Nemerow, and S.J. Shattil Mechanisms and consequences of affinity modulation of integrin alpha(V)beta(3) detected with a novel patch-engineered monovalent ligand J Biol Chem 274 1999 21609 21616
51. J. Kapyla, J. Jaalinoja, M. Tulla, J. Ylostalo, L. Nissinen, T. Viitasalo, P. Vehvilainen, V. Marjomaki, P. Nykvist, A.M. Saamanen, R.W. Farndale, D.E. Birk, L. Ala-Kokko, and J. Heino The fibril-associated collagen IX provides a novel mechanism for cell adhesion to cartilaginous matrix J Biol Chem 279 2004 51677 51687 (Pubitemid 40017919)
52. M. Fukunaga-Kalabis, A. Santiago-Walker, and M. Herlyn Matricellular proteins produced by melanocytes and melanomas: in search for functions Cancer Microenviron 1 2008 93 102
53. S.M. Albelda, S.A. Mette, D.E. Elder, R. Stewart, L. Damjanovich, M. Herlyn, and C.A. Buck Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression Cancer Res 50 1990 6757 6764 (Pubitemid 20348810)
54. M.Y. Hsu, D.T. Shih, F.E. Meier, P. Van Belle, J.Y. Hsu, D.E. Elder, C.A. Buck, and M. Herlyn Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma Am J Pathol 153 1998 1435 1442 (Pubitemid 28509899)
55. S.A. Khan, A.C. Cook, M. Kappil, U. Gunthert, A.F. Chambers, A.B. Tuck, and D.T. Denhardt Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation Clin Exp Metastasis 22 2005 663 673 (Pubitemid 44259527)
56. J.L. Lee, M.J. Wang, P.R. Sudhir, G.D. Chen, C.W. Chi, and J.Y. Chen Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells Cancer Res 67 2007 2089 2097
57. E. Geissinger, C. Weisser, P. Fischer, M. Schartl, and C. Wellbrock Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen Cancer Res 62 2002 4820 4828
58. H.T. Maecker, S.C. Todd, and S. Levy The tetraspanin superfamily: molecular facilitators FASEB J 11 1997 428 442 (Pubitemid 27259984)
59. B. Ryu, D.S. Kim, A.M. Deluca, and R.M. Alani Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression PLoS One 2 2007 e594
60. J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A.A. Margolin, and S. Kim et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature 483 2012 603 607
61. C. Haqq, M. Nosrati, D. Sudilovsky, J. Crothers, D. Khodabakhsh, B.L. Pulliam, S. Federman, J.R. Miller 3rd, R.E. Allen, M.I. Singer, S.P. Leong, B.M. Ljung, R.W. Sagebiel, and M. Kashani-Sabet The gene expression signatures of melanoma progression Proc Natl Acad Sci U S A 102 2005 6092 6097 (Pubitemid 40594260)
62. G.F. Weber The cancer biomarker osteopontin: combination with other markers Cancer Genomics Proteomics 8 2011 263 288
63. H.M. Kluger, K. Hoyt, A. Bacchiocchi, T. Mayer, J. Kirsch, Y. Kluger, M. Sznol, S. Ariyan, A. Molinaro, and R. Halaban Plasma markers for identifying patients with metastatic melanoma Clin Cancer Res 17 2011 2417 2425
64. T. Maier, R.P. Laubender, R.A. Sturm, A. Klingenstein, H.C. Korting, T. Ruzicka, and C. Berking Osteopontin expression in plasma of melanoma patients and in melanocytic tumours J Eur Acad Dermatol Venereol 26 2012 1084 1091
65. A.L. Allan, R. George, S.A. Vantyghem, M.W. Lee, N.C. Hodgson, C.J. Engel, R.L. Holliday, D.P. Girvan, L.A. Scott, C.O. Postenka, W. Al-Katib, L.W. Stitt, T. Uede, A.F. Chambers, and A.B. Tuck Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer Am J Pathol 169 2006 233 246
66. M.L. Shinohara, H.J. Kim, J.H. Kim, V.A. Garcia, and H. Cantor Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells Proc Natl Acad Sci U S A 105 2008 7235 7239 (Pubitemid 351754461)
67. B. He, M. Mirza, and G.F. Weber An osteopontin splice variant induces anchorage independence in human breast cancer cells Oncogene 25 2006 2192 2202
68. M. Mirza, E. Shaughnessy, J.K. Hurley, K.A. Vanpatten, G.A. Pestano, B. He, and G.F. Weber Osteopontin-c is a selective marker of breast cancer Int J Cancer 122 2008 889 897
69. D. Courter, H. Cao, S. Kwok, C. Kong, A. Banh, P. Kuo, D.M. Bouley, C. Vice, O.T. Brustugun, N.C. Denko, A.C. Koong, A. Giaccia, and Q.T. Le The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways PLoS One 5 2010 e9633
70. J.T. Reilly, and J.R. Nash Vitronectin (serum spreading factor): its localisation in normal and fibrotic tissue J Clin Pathol 41 1988 1269 1272 (Pubitemid 19005665)
71. P. Brodt Adhesion mechanisms in lymphatic metastasis Cancer Metastasis Rev 10 1991 23 32
72. K.T. Preissner Structure and biological role of vitronectin Annu Rev Cell Biol 7 1991 275 310
73. J. Nip, H. Shibata, D.J. Loskutoff, D.A. Cheresh, and P. Brodt Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin J Clin Invest 90 1992 1406 1413
74. J.S. Desgrosellier, and D.A. Cheresh Integrins in cancer: biological implications and therapeutic opportunities Nat Rev Cancer 10 2010 9 22
75. S. O'Day, A. Pavlick, C. Loquai, D. Lawson, R. Gutzmer, J. Richards, D. Schadendorf, J.A. Thompson, R. Gonzalez, U. Trefzer, P. Mohr, C. Ottensmeier, D. Chao, B. Zhong, C.J. de Boer, C. Uhlar, D. Marshall, M.E. Gore, Z. Lang, W. Hait, and P. Ho CNTO 95 Investigators: a randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma Br J Cancer 105 2011 346 352
76. Y.U. Katagiri, J. Sleeman, H. Fujii, P. Herrlich, H. Hotta, K. Tanaka, S. Chikuma, H. Yagita, K. Okumura, M. Murakami, I. Saiki, A.F. Chambers, and T. Uede CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis Cancer Res 59 1999 219 226 (Pubitemid 29062981)
77. M.E. Hemler Tetraspanin functions and associated microdomains Nat Rev Mol Cell Biol 6 2005 801 811 (Pubitemid 41726118)
78. M. Zoller Tetraspanins: push and pull in suppressing and promoting metastasis Nat Rev Cancer 9 2009 40 55
79. E. Rubinstein The complexity of tetraspanins Biochem Soc Trans 39 2011 501 505
80. M.M. Richardson, L.K. Jennings, and X.A. Zhang Tetraspanins and tumor progression Clin Exp Metastasis 28 2011 261 270
81. H.M. Romanska, and F. Berditchevski Tetraspanins in human epithelial malignancies J Pathol 223 2011 4 14
82. P. Kischel, A. Bellahcene, B. Deux, V. Lamour, R. Dobson, E. DE Pauw, P. Clezardin, and V. Castronovo Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases Anticancer Res 32 2012 5211 5220
83. S. Ikeyama, M. Koyama, M. Yamaoko, R. Sasada, and M. Miyake Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA J Exp Med 177 1993 1231 1237 (Pubitemid 23117114)
84. M. Miyake, H. Inufusa, M. Adachi, H. Ishida, H. Hashida, T. Tokuhara, and Y. Kakehi Suppression of pulmonary metastasis using adenovirally motility related protein-1 (MRP-1/CD9) gene delivery Oncogene 19 2000 5221 5226
85. T. Takeda, N. Hattori, T. Tokuhara, Y. Nishimura, M. Yokoyama, and M. Miyake Adenoviral transduction of MRP-1/CD9 and KAI1/CD82 inhibits lymph node metastasis in orthotopic lung cancer model Cancer Res 67 2007 1744 1749 (Pubitemid 46383401)
86. M. Miyake, K. Nakano, Y. Ieki, M. Adachi, C.L. Huang, S. Itoi, T. Koh, and T. Taki Motility related protein 1 (MRP-1/CD9) expression: inverse correlation with metastases in breast cancer Cancer Res 55 1995 4127 4131
87. M. Higashiyama, O. Doi, K. Kodama, H. Yokouchi, M. Adachi, C.L. Huang, T. Taki, T. Kasugai, S. Ishiguro, S. Nakamori, and M. Miyake Immunohistochemically detected expression of motility-related protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to prognosis Int J Cancer 74 1997 205 211 (Pubitemid 27234512)
88. J.C. Wang, L.R. Begin, N.G. Berube, S. Chevalier, A.G. Aprikian, H. Gourdeau, and M. Chevrette Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications Clin Cancer Res 13 2007 2354 2361 (Pubitemid 46698584)
89. M. Mori, K. Mimori, T. Shiraishi, M. Haraguchi, H. Ueo, G.F. Barnard, and T. Akiyoshi Motility related protein 1 (MRP1/CD9) expression in colon cancer Clin Cancer Res 4 1998 1507 1510 (Pubitemid 28265235)
90. Z. Si, and P. Hersey Expression of the neuroglandular antigen and analogues in melanoma. CD9 expression appears inversely related to metastatic potential of melanoma Int J Cancer 54 1993 37 43 (Pubitemid 23136996)
91. M. Higashiyama, T. Taki, Y. Ieki, M. Adachi, C.L. Huang, T. Koh, K. Kodama, O. Doi, and M. Miyake Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer Cancer Res 55 1995 6040 6044
92. M. Miyake, K. Nakano, S.I. Itoi, T. Koh, and T. Taki Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer Cancer Res 56 1996 1244 1249 (Pubitemid 26080963)
93. M. Sho, M. Adachi, T. Taki, H. Hashida, T. Konishi, C.L. Huang, N. Ikeda, Y. Nakajima, H. Kanehiro, M. Hisanaga, H. Nakano, and M. Miyake Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer Int J Cancer 79 1998 509 516 (Pubitemid 28445274)
94. P. Mhawech, P. Dulguerov, E. Tschanz, C. Verdan, C. Ares, and A.S. Allal Motility-related protein-1 (MRP-1/CD9) expression can predict disease-free survival in patients with squamous cell carcinoma of the head and neck Br J Cancer 90 2004 471 475 (Pubitemid 38250647)
95. S. Uchida, Y. Shimada, G. Watanabe, Z.G. Li, T. Hong, M. Miyake, and M. Imamura Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma Br J Cancer 79 1999 1168 1173 (Pubitemid 29087892)
96. J. Kusukawa, F. Ryu, T. Kameyama, and E. Mekada Reduced expression of CD9 in oral squamous cell carcinoma: CD9 expression inversely related to high prevalence of lymph node metastasis J Oral Pathol Med 30 2001 73 79 (Pubitemid 32102985)
97. C.L. Huang, D. Liu, D. Masuya, K. Kameyama, T. Nakashima, H. Yokomise, M. Ueno, and M. Miyake MRP-1/CD9 gene transduction downregulates Wnt signal pathways Oncogene 23 2004 7475 7483 (Pubitemid 39389689)
98. Y. Saito, I. Tachibana, Y. Takeda, H. Yamane, P. He, M. Suzuki, S. Minami, T. Kijima, M. Yoshida, T. Kumagai, T. Osaki, and I. Kawase Absence of CD9 enhances adhesion-dependent morphologic differentiation, survival, and matrix metalloproteinase-2 production in small cell lung cancer cells Cancer Res 66 2006 9557 9565 (Pubitemid 44623654)
99. S. Ovalle, M.D. Gutierrez-Lopez, N. Olmo, J. Turnay, M.A. Lizarbe, P. Majano, F. Molina-Jimenez, M. Lopez-Cabrera, M. Yanez-Mo, F. Sanchez-Madrid, and C. Cabanas The tetraspanin CD9 inhibits the proliferation and tumorigenicity of human colon carcinoma cells Int J Cancer 121 2007 2140 2152 (Pubitemid 47585592)
100. F. Berditchevski Complexes of tetraspanins with integrins: more than meets the eye J Cell Sci 114 2001 4143 4151 (Pubitemid 33138652)
101. A.C. Cook, A.B. Tuck, S. McCarthy, J.G. Turner, R.B. Irby, G.C. Bloom, T.J. Yeatman, and A.F. Chambers Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression Mol Carcinog 43 2005 225 236 (Pubitemid 41134430)